Unidad Médica de Alta Especialidad, Hospital de Especialidades No. 14, Centro Médico Nacional Adolfo Ruiz Cortines, Instituto Mexicano del Seguro Social (IMSS), Veracruz, Mexico.
Unidad Médica de Alta Especialidad, Hospital de Especialidades No. 14, Centro Médico Nacional Adolfo Ruiz Cortines, Instituto Mexicano del Seguro Social (IMSS), Veracruz, Mexico; Facultad de Medicina, Región Veracruz, Universidad Veracruzana, Veracruz, Mexico.
Arch Soc Esp Oftalmol (Engl Ed). 2023 May;98(5):259-264. doi: 10.1016/j.oftale.2023.04.009. Epub 2023 Apr 18.
Although the ophthalmic manifestations appear to be associated with the coronavirus disease 2019 (COVID-19), there is not enough evidence. Hence, the aim of this study was to determine the various types and frequency of ophthalmic manifestations in patients recovered from SARS-CoV-2 infection in Mexico.
This retrospective, observational and descriptive study included all patients recovered from SARS-CoV-2 infection attending the tertiary level hospital of Mexican Social Security Institute (IMSS) from June 2020 to June 2022. During the hospital admission of patients, the demographic data such age, name, gender was recorded. Ophthalmologic examination was performed under torchlight by an ophthalmologist in the Department of Ophthalmology from IMSS. Data was compiled and statistically analyzed using Fisher's exact test and Spearman correlation.
A total of 3081 SARS-CoV-2-positive patients were recorded, of which 318 (10.32%) met the inclusion criteria. Of them, 21 (6.60%) had ophthalmic manifestations and the female-to-male ratio was 1.6:1. The mean age (±SD) was 47.95±15.27 years and the median (interquartile range) time from the diagnosis of COVID-19, as defined by positive SARS-CoV-2 RT-PCR testing, to detection of the ophthalmic manifestation was 31 (142) days. The most common ocular manifestation was orbital mucormycosis (23.80%). Interestingly, the presence of ophthalmic manifestations was not associated with severe COVID-19 (p=0.665).
The ophthalmic manifestations are infrequent in patients recovered from severe COVID-19. Nevertheless, further large sample studies are needed to confirm these findings.
尽管眼部表现似乎与 2019 年冠状病毒病（COVID-19）有关，但目前证据不足。因此，本研究的目的是确定在墨西哥从 SARS-CoV-2 感染中康复的患者的各种眼部表现类型和频率。
这是一项回顾性、观察性和描述性研究，包括 2020 年 6 月至 2022 年 6 月期间在墨西哥社会保障研究所（IMSS）三级医院就诊的所有从 SARS-CoV-2 感染中康复的患者。在患者住院期间，记录了年龄、姓名、性别等人口统计学数据。由 IMSS 眼科系的眼科医生在手电筒下进行眼科检查。使用 Fisher 确切检验和 Spearman 相关分析对数据进行编译和统计分析。
共记录了 3081 例 SARS-CoV-2 阳性患者，其中 318 例（10.32%）符合纳入标准。其中，21 例（6.60%）有眼部表现，男女比例为 1.6:1。平均年龄（±SD）为 47.95±15.27 岁，从 COVID-19 诊断（定义为 SARS-CoV-2 RT-PCR 检测阳性）到发现眼部表现的中位（四分位间距）时间为 31（142）天。最常见的眼部表现是眼眶毛霉菌病（23.80%）。有趣的是，眼部表现的存在与严重 COVID-19 无关（p=0.665）。
从严重 COVID-19 中康复的患者眼部表现不常见。然而，需要进一步的大样本研究来证实这些发现。
Zotero 插件